Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Rev. méd. Panamá ; 42(2): 34-40, ago 2022.
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1391711

RESUMO

Introducción: Los mesoteliomas peritoneales se origina de las células que recubren la serosa de las cavidades del cuerpo, el 15% se originan del peritoneo. Su incidencia de es 0.2 a 3 casos por millones de personal al año. Son tumores raros y su supervivencia global se limita hasta 12 meses. El objetivo de esta presentación de caso es describir una presentación atípica de esta entidad y realizar una revisión de la literatura. Materiales y métodos: Se realizó una descripción de un caso en la consulta externa de oncología diagnosticada con Mesotelioma papilar bien diferenciado de primario de peritoneo diagnosticada en el 2012 quien en el 2022 mantiene 10 años de supervivencia global y se realizó una revisión de la literatura en base al caso clínico. Resultados:  Se define los tipos de mesotelioma peritoneal, sus características clínicas, el manejo del Mesotelioma Peritoneal según el Consenso de Chicago, los principios en cuidados de soporte como la ascitis peritoneal, el dolor, náuseas y vómitos, distrés psicosocial, así como la discusión del caso. Conclusión: El mesotelioma peritoneal es una enfermedad rara que puede ser rápidamente progresiva con una carga de enfermedad importante y pronóstico limitado. La instauración temprana de cuidados paliativos en pacientes con neoplasia incurable como el mesotelioma peritoneal permite el abordaje una mejor calidad de vida del paciente, así como de cumplir objetivos acordes a la situación clínica de cada paciente. (provisto por Infomedic International)


Introduction: Peritoneal mesotheliomas originate from the cells lining the serosa of the body cavities, 15% originate from the peritoneum. Their incidence is 0.2 to 3 cases per million personnel per year. They are rare tumors and their overall survival is limited to 12 months. The aim of this case report is to describe an atypical presentation of this entity and to review the literature. Materials and methods: A description of a case was made in the oncology outpatient clinic diagnosed with well-differentiated papillary mesothelioma of primary peritoneum diagnosed in 2012 who in 2022 maintains 10 years of overall survival and a review of the literature was performed based on the clinical case. Results: We define the types of peritoneal mesothelioma, its clinical features, the management of peritoneal mesothelioma according to the Chicago Consensus, the principles in supportive care such as peritoneal ascites, pain, nausea and vomiting, psychosocial distress, as well as the discussion of the case. Conclusion: Peritoneal mesothelioma is a rare disease that can be rapidly progressive with a significant disease burden and limited prognosis. The early establishment of palliative care in patients with incurable neoplasm such as peritoneal mesothelioma allows the approach to a better quality of life of the patient, as well as to meet objectives according to the clinical situation of each patient. (provided by Infomedic International)

2.
Case Rep Oncol ; 14(2): 989-997, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34326733

RESUMO

Myoepithelial carcinoma of the salivary glands is a rare entity, with scarce amount of case reports in the literature. Due to its infrequency, its diagnosis is usually difficult and uncertain. Although there are reports of locoregional recurrences and distant metastases, its low incidence and varied biological behavior limits the clinical evidence that can be used to predict the prognosis and determine the course of treatment. We present a 23-year-old female patient without past medical history with an initial 1-year history of volume increase in the right parotid region of tumor aspect and painful on palpation. As a malignancy was suspected, a total parotidectomy was performed, reporting in the deep lobe a parotid myoepithelial carcinoma with vascular and neural invasion, negative borders, and 3-9 negative regional nodes. During her 16-year clinical evolution, she presented approximately every 2 years and a total of 9 locoregional recurrences and hepatic metastases, including cervical lymphoid nodules, temporal bone, frontal bone, and temporal fossa. Those recurrences have been treated with coordinated efforts between repeated external radiotherapy, chemotherapy, and multiple surgical resections. Myoepithelial tumors represent only 1.0-1.5% of all salivary gland tumors. The literature reports suggest a high incidence of locoregional recurrences and distant metastases in de novo myoepithelial carcinomas. Due to its rarity, treatment continues to be based on the experience of medical staff.

3.
Future Oncol ; 17(13): 1601-1609, 2021 May.
Artigo em Inglês | MEDLINE | ID: mdl-33415992

RESUMO

Aim: FLABRA evaluated the prevalence of BRCA mutations, genetic counseling and management approaches in patients with ovarian cancer in Latin America. Patients & methods: Patients with ovarian cancer from six Latin-American countries were enrolled. Tumor samples were tested for BRCA mutations (BRCAmut). In cases with BRCAmut, blood samples were analyzed to determine germline versus somatic mutations. Medical records were reviewed for counseling approach and treatment plan. Results: From 472 patients enrolled, 406 samples yielded conclusive results: 282 were BRCA wild-type (BRCAwt), 115 were BRCAmut and nine were variants of uncertain significance. In total, 110/115 were tested for germline mutations (77 germline and 33 somatic). Conclusion: Tumor testing to identify mutations in BRCA1/2 in ovarian cancer can help optimize treatment choices, meaning fewer patients require germline testing and genetic counseling, a scant resource in Latin America. Clinical trial registration: NCT02984423 (ClinicalTrials.gov).


Assuntos
Carcinoma Epitelial do Ovário/diagnóstico , Testes Genéticos/estatística & dados numéricos , Neoplasias Ovarianas/diagnóstico , Adulto , Idoso , Proteína BRCA1/genética , Proteína BRCA2/genética , Carcinoma Epitelial do Ovário/epidemiologia , Carcinoma Epitelial do Ovário/genética , Carcinoma Epitelial do Ovário/terapia , Estudos Transversais , Análise Mutacional de DNA/economia , Análise Mutacional de DNA/estatística & dados numéricos , Feminino , Aconselhamento Genético/economia , Aconselhamento Genético/estatística & dados numéricos , Testes Genéticos/economia , Humanos , América Latina/epidemiologia , Pessoa de Meia-Idade , Neoplasias Ovarianas/epidemiologia , Neoplasias Ovarianas/genética , Neoplasias Ovarianas/terapia , Medicina de Precisão/métodos , Prevalência , Estudos Prospectivos , Adulto Jovem
4.
Rev. méd. Panamá ; 40(1): 30-35, ene.2020. ilus, tab
Artigo em Espanhol | LILACS | ID: biblio-1099684

RESUMO

Introducción: Los costes informales derivan de cuidados informales que es la atención prestada a un enfermo o discapacitado por parte de personas que no son profesionales socio sanitarios y que no reciben una remuneración económica. El objetivo del trabajo es explicar los costes informales en salud, su definición, su obtención, análisis y el im­ pacto en su incorporación en las evaluaciones económicas en salud. Materiales y métodos: Se realizó una búsqueda del tema sobre costes informales en la base de datos de Medline­Pubmed y en la búsqueda de la biblioteca de la Universidad Carlos III Madrid vía internet a través de varias bases de datos como EconLit y ABI/IN­ FORM collection. Resultados: Se define los cuidados informales, los métodos para su medición en tiempo, en preferencias reveladas, preferencias establecidos fijados, otros métodos, la importan­ cia de incorporar los costos informales en las evaluaciones económicas en salud. Conclusión: La evaluación económica a nivel de la perspectiva de la sociedad se debe incluir, pero muchas veces se realiza según el pagador por lo difícil que puede ser su medición.


Introduction: Informal costs derive from informal care, which is the care provided to a sick or disabled person by people who are not socio­health professionals and who do not receive financial compensation. The objective of the work is to explain the informal costs in health, its definition, its obtaining, analysis and the impact on its incorporation in the economic health evaluations. Material and methods: A search of the topic on informal costs was carried out in the Medli­ ne­Pubmed database and in the search of the Carlos III Madrid University library via the In­ ternet through several databases such as EconLit and ABI / INFORM collection. Results: Informal care is defined, the methods for its measurement in time, in revealed preferences, established preferences, other methods, the importance of incorporating informal costs in economic health evaluations. Conclusion: The economic evaluation at the level of the society perspective must be in­ cluded, but many times it is carried out according to the payer because of how difficult its measurement can be done


Assuntos
Avaliação em Saúde , Cuidadores/economia , Economia Médica/organização & administração , Qualidade de Vida/psicologia , Bases de Dados Bibliográficas , Avaliação das Necessidades
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...